NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease with Inflammatory Complications

This study is currently recruiting participants.

Summary | Eligibility | Citations | Contacts




Sponsoring Institute

National Institute of Allergy and Infectious Diseases (NIAID)

Recruitment Detail

Type: Enrolling by Invitation
Gender: Male & Female
Min Age: 18 Years
Max Age: 99 Years

Referral Letter Required


Population Exclusion(s)

Pregnant Women;


Inflammatory Bowel Disease;
Interferon (IFN)-induced gene expression;
JAK Inhibitor;
Ulcerative Colitis;
Inflammatory skin/ lung disease

Recruitment Keyword(s)



Chronic Granulomatous Disease;
Inflammatory gastrointestinal disease;
Inflammatory skin disease;
Inflammatory lung disease

Investigational Drug(s)

XELJANZ (tofacitinib)

Investigational Device(s)



Drug: XELJANZ (tofacitinib)

Supporting Site

National Institute of Allergy and Infectious Diseases


Chronic granulomatous disease (CGD) is a disease of the immune system, which is how the body fights germs. People with CGD get infections easily and have other health problems. Some medicines to treat CGD have a lot of side effects and do not always work. Researchers want to see if a new drug can help.


To see if tofacitinib is safe to use for treating chronic CGD.


Adults aged 18 and older with CGD who have not had success with other treatments and who are enrolled on NIH study # 93-I-0119.


Participants will be screened with the following:

Physical exam

Medical history

Blood, urine, and stool tests

Pregnancy test, if needed

An upper gastrointestinal endoscopy and/or colonoscopy, if needed for their symptoms. Tissue samples will be collected.

Skin assessment, if needed

Participants will repeat some screening tests at visits.

Participants will complete questionnaires about their general health and how CGD affects their daily life. Photographs will be taken of their skin, if needed. They will have lung function tests, if needed. They will have a computed tomography (CT) scan of the chest, abdomen, and pelvis, if needed. A CT scan uses X-rays to create pictures of the inside of the body.

Participants will gradually reduce the amount of some CGD medicines they take. Then they will take tofacitinib as a pill twice a day or once a day for 3 months. They will keep a drug diary. They will have monthly study visits. They will have a follow-up visit about 1 month after their last study drug visit.

Participation will last for about 6 months.

--Back to Top--



In order to be eligible to participate in this study, an individual must meet all of the following criteria:

1. Aged >=18 years.

2. Enrolled on NIH study 93-I-0119.

3. Has a documented diagnosis of one or more of the following and is not controlled under current therapy (per investigator assessment):

a. Endoscopically diagnosed mild-to-severe CGD-related IBD.

b. Radiographic or PFT changes (DLCO<60%, FEV1<70%) consistent with CGD-related inflammatory lung disease.

c. Any inflammatory skin disease related to CGD (eg, hidradenitis suppurativa or granulomatous skin disease).

4. Able to provide informed consent.

5. Participants who can become pregnant or who can impregnate their partner must agree to use at least one highly effective method of contraception when engaging in sexual activities that can result in pregnancy, starting at the first dose of tofacitinib until 2 days after the last dose. Highly effective methods include a barrier (eg, condom, diaphragm, cervical cap), intrauterine device, or hormonal contraception.


An individual who meets any of the following criteria will be excluded from participation in this study:

1. Known allergy or hypersensitivity to any component of the tofacitinib formulation.

2. Known allergy or hypersensitivity to any component of the acyclovir or valacyclovir formulation.

3. Active or latent tuberculosis.

4. Infection with hepatitis B or C, or HIV.

5. Active EBV infection.

6. History of GI perforation.

7. History of malignancy (except for nonmelanoma skin cancer).

8. Concomitant use of acetylsalicylic acid and/or NSAIDs that cannot be safely discontinued.

9. History of connective tissue disease.

10. End-stage renal disease or chronic kidney disease, defined as estimated glomerular filtration rate (eGFR) <15 mL/min/1.73 m^2.

11. Evidence of other invasive or systemic fungal, bacterial, or viral infections requiring therapy.

12. Pregnant.

13. Breastfeeding.

14. Current use of inhaled tobacco products, vaping product, inhaled cannabis, or other illicit inhaled drugs.

15. Current use of strong CYP3A4 inducer and unable to discontinue at least 14 days before beginning of tofacitinib regimen.

16. Concomitant medical condition that could interfere with study drug evaluation or that is a contraindication to the proposed investigational treatment based upon known agent safety profile or toxicities.

17. Any of the following laboratory abnormalities:

a. Alkaline phosphatase and either ALT or AST >2.5 times the upper limit of normal (ULN).

b. Serum creatinine level >5 mg/dL.

c. Absolute neutrophil count (ANC) <1000 cells/microL.

d. Lymphocyte count <500 cells/microL.

18. History of unprovoked deep vein thrombosis, pulmonary embolism, or other thrombotic events.

19. History of heart failure.

20. Current immobilization, ie, bed-bound and unable to ambulate.

21. Exposure to any investigational agent within the last 4 weeks.

22. Any other finding that, in the judgment of the investigator, would interfere with, or serve as a contraindication to, protocol adherence, assessment of safety or reactogenicity, or a participant s ability to give informed consent, or increase the risk of having an adverse outcome from participating in the study.

--Back to Top--


Pan(SqrRoot)(Copyright)s J, Sandborn WJ, Schreiber S, Sands BE, Vermeire S, D'Haens G, Panaccione R, Higgins PDR, Colombel JF, Feagan BG, Chan G, Moscariello M, Wang W, Niezychowski W, Marren A, Healey P, Maller E. Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. Gut. 2017 Jun;66(6):1049-1059. doi: 10.1136/gutjnl-2016-312735. Epub 2017 Feb 16. PMID: 28209624; PMCID: PMC5532457.

Henrickson SE, Jongco AM, Thomsen KF, Garabedian EK, Thomsen IP. Noninfectious Manifestations and Complications of Chronic Granulomatous Disease. J Pediatric Infect Dis Soc. 2018 May 9;7(suppl_1):S18-S24. doi: 10.1093/jpids/piy014. PMID: 29746679; PMCID: PMC5946858.

--Back to Top--


Principal Investigator

Referral Contact

For more information:

Christa S. Zerbe, M.D.
National Institute of Allergy and Infectious Diseases (NIAID)
(301) 594-5932

Christine J. Lafeer, R.N.
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health
Building 3
Room 1W23
3 Center Drive
Bethesda, Maryland 20892
(301) 761-6902

Office of Patient Recruitment
National Institutes of Health Clinical Center (CC)
Building 61, 10 Cloister Court
Bethesda, Maryland 20892
Toll Free: 1-800-411-1222
Local Phone: 301-451-4383
TTY: TTY Users Dial 7-1-1

Clinical Trials Number:


--Back to Top--